emerging markets Archives -

Moderna has unveiled plans to start clinical trials of mRNA-based vaccines for 15 infectious diseases that pose the

Moderna targets 15 pathogens in ‘global public health strategy’

https://pharmaphorum.com/news/moderna-targets-15-pathogens-in-global-public-health-strategy/

Data hackathon analyses truth behind ‘game-changer’ COVID vaccine

R&D/ Views & Analysis/ Views and analysis

COVID-19 underscores need to boost pharma manufacturing in emerging markets

Catherine Longworth COVID-19, emerging markets, manufacturing, vaccines 0 Comment

For the past year, life science companies around the world worked at breakneck speed to develop and manufacture

COVID-19 underscores need to boost pharma manufacturing in emerging markets

https://pharmaphorum.com/views-and-analysis/covid-underscores-need-to-boost-pharma-manufacturing-in-emerging-markets/

Market Access/ Partner content/ Press releases

Windrose Consulting Group acquires Parioforma

Matt Storer emerging markets, market access, pharma, pricing, Pricing and Market Access 0 Comment

Windrose acquires Parioforma as part of growth strategy

Windrose Consulting Group acquires Parioforma

https://pharmaphorum.com/partner-content/windrose-consulting-group-acquires-parioforma/

Market Access/ Views & Analysis/ Views and analysis

The real impact of COVID-19 on emerging markets

mike.hammerton@pharmaphorum.com coronavirus, COVID-19, emerging markets 0 Comment

When COVID-19 began to spread uncontrollably, numbers of confirmed cases initially grew most quickly in developed economies across

The real impact of COVID-19 on emerging markets

https://pharmaphorum.com/views-analysis-market-access/the-real-impact-of-covid-19-on-emerging-markets/

Market Access/ Views & Analysis/ Views and analysis

Q&A: Zulf Masters on emerging markets

George Underwood emerging markets, Masters Speciality Pharma 0 Comment

UK-based Masters Speciality Pharma focuses on supplying medicines to developing countries where access to treatments is limited –

Q&A: Zulf Masters on emerging markets

https://pharmaphorum.com/views-analysis-market-access/qa-zulf-masters-on-emerging-markets/

News/ News/ Sales and Marketing

Takeda nets $660m from product selloff to Germany’s Stada

Phil Taylor emerging markets, generic, OTC, Russia, Stada, Takeda 0 Comment

Takeda has divested another block of products it views as lying outside its main focus, selling various drugs

Takeda nets $660m from product selloff to Germany’s Stada

https://pharmaphorum.com/news/takeda-nets-660m-from-product-selloff-to-germanys-stada/

Market Access/ Views & Analysis/ Views and analysis

Navigating emerging markets – opportunities and challenges for pharma

mike.hammerton@pharmaphorum.com BRIC, emerging markets, Natalie Yeadon 0 Comment

The pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of

Navigating emerging markets – opportunities and challenges for pharma

https://pharmaphorum.com/views-analysis-market-access/navigating-emerging-markets-opportunities-and-challenges-for-pharma/

Events/ Events

Global Pharmaceutical Regulatory Affairs Summit

eleni.vamvakopoulou@knect365.com emerging markets

Connect with regulators and industry peers

Global Pharmaceutical Regulatory Affairs Summit

https://pharmaphorum.com/events/global-pharmaceutical-regulatory-affairs-summit/

Articles/ Deep Dive/ Pharma Market Access/ Views and analysis

MINT: opportunities in ‘frontier’ markets?

Linda Banks emerging markets, Indonesia, market access, Mexico, MINT, new pharma markets, Nigeria, Turkey 0 Comment

The prospects for pharma in the MINT emerging countries of Mexico, Indonesia, Nigeria and Turkey.

MINT: opportunities in ‘frontier’ markets?

https://pharmaphorum.com/articles/mint-opportunities-frontier-markets/

Trending

emerging markets

Login